Ruxolitinib-containing Rescue Therapy for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis: A Target Trial Emulation Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #906; Pres time: Nov 8, 2026; 02:00 PM - 02:15 PM; Location: W206; In Person; "IVIG, intravenous immunoglobulin. In refractory anti-MDA5 positive dermatomyositis-associated RPILD, a ruxolitinib-containing rescue strategy was associated with lower 6-month mortality and biomarker trajectories consistent with JAK1/2-mediated pathway suppression, but at the cost of increased viral reactivation risks. Prospective validation is warranted. Table 1."
Dermatomyositis • Immunology • Infectious Disease • Interstitial Lung Disease • Melanoma • Myositis • Pulmonary Disease • Respiratory Diseases • Solid Tumor • CRP • IFIH1 • JAK1
|
|
Yiyun Pang1; Jiyuan Zhou1; Jingjing Shang2; Chen Yu3; Chanyuan Wu4; Le Yu2; Dong Xu5; Jiuliang Zhao3; Jun Xu6; Di Shi6; Jinmin Peng7; Shuang Zhou1; Xinwang Duan2; Xiaofeng Zeng8; Mengtao Li9; Qian Wang1
|